Intended for licensed healthcare professionals located in the United Kingdom and Republic of Ireland only

UK prescribing information ROI prescribing information UK SmPC ROI SmPC Report an adverse event
ESMO guideline recommendations FGFR2 fusion testing
About PEMAZYRE
Efficacy Safety FAQs
Dosing and administration Request a meeting Stay informed Resources

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events.

Resources

shared.diamonds shared.diamonds
Star icon

Featured Content

Nurse's Handbook thumbnail

Nurse's Handbook

View a guide for nurses managing patients on PEMAZYRE, developed in collaboration with UK nurses.

Eye icon View
resources.latest.pdfs.icon.alt

Latest PDFs

View all
Nurse's Handbook thumbnail

Nurse's Handbook

Eye icon View
Pharmacy Manual (UK) thumbnail

Pharmacy Manual (UK)

Eye icon View
ESMO 2025 Guideline for Biliary Tract Cancer thumbnail

ESMO 2025 Guideline for Biliary Tract Cancer

Eye icon View
AE management & dosing guide thumbnail

AE management & dosing guide

Eye icon View
resources.latest.videos.icon.alt

Latest Videos

View all
Patient perspectives (1/5): Diagnosis thumbnail

Patient perspectives (1/5): Diagnosis

Eye icon View
Patient perspectives (2/5): Journey to PEMAZYRE thumbnail

Patient perspectives (2/5): Journey to PEMAZYRE

Eye icon View
Patient perspectives (3/5): Starting PEMAZYRE treatment thumbnail

Patient perspectives (3/5): Starting PEMAZYRE treatment

Eye icon View
Patient perspectives (4/5): Experience with PEMAZYRE thumbnail

Patient perspectives (4/5): Experience with PEMAZYRE

Eye icon View
Patient perspectives (5/5): Reflections on treatment thumbnail

Patient perspectives (5/5): Reflections on treatment

Eye icon View

Download

Privacy Policy Cookie Policy Terms of Use If you would like to request further medical information, please visit:
https://www.incyteglobalmedicalinformation.com/
Marketing authorisation holder:
United Kingdom
Incyte Biosciences UK Ltd,
First Floor Q1, The Square,
Randalls Way, Leatherhead,
KT22 7TW, UK

Republic of Ireland
Incyte Biosciences Distribution B.V.
Paasheuvelweg 25,
1105 BP Amsterdam, Netherlands

UNITED KINGDOM
Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Incyte by calling 00‑800‑0002‑7423.

REPUBLIC OF IRELAND
Adverse events should be reported.Reporting forms and information can be found at HPRA Pharmacovigilance: www.hpra.ie. Adverse events should also be reported to Incyte immediately by phoning the Toll-free phone number 1800‑456‑748.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

This medicinal product has been authorised under a 'conditional approval' scheme. This means that further evidence on this medicinal product is awaited.

IE/PEMA/P/25/0012
Date of preparation: April 2025
Developed and funded by Incyte Biosciences International Sàrl.
© 2025, Incyte. All rights reserved.
PEMAZYRE, the PEMAZYRE logo and the Incyte logo are registered trademarks of Incyte.

Back to top

External link disclaimer

Intended for licensed healthcare professionals located in the United Kingdom and Republic of Ireland only.

You are now leaving the Incyte PEMAZYRE website. This link will take you to a site that is not owned or maintained by Incyte. Incyte is not responsible for the information contained on third⁠–⁠party sites. Would you like to continue?

Yes No

Report an adverse event

Caution

Intended for licensed healthcare professionals located in the United Kingdom and Republic of Ireland only.

You are now leaving the Incyte PEMAZYRE website. This link will take you to the site https://www.incyte.com, owned by Incyte Corporation and managed by the company. Would you like to continue?

Yes No

Report an adverse event

Want to be kept up to date with the latest news in oncology? Complete this quick form to receive relevant information from Incyte

Yes please No thanks